Advertisement

Elective Pregnancy Termination

  • Cassing Hammond
  • Sheila Mody
Chapter

Abstract

An important part of helping a woman safely through any pregnancy involves knowing how to safely end that pregnancy. Although inducing delivery of a term or preterm infant prompts limited conceptual dissent, inducing abortion to end a medically troubled or undesired pregnancy troubles some physicians and preoccupies many politicians. Meanwhile, half of all pregnancies in the United States are unintended. 22% of all pregnancies and 40% of unintended pregnancies undergo pregnancy termination. Each year in the United States, 2% of reproductive age women undergo abortion, and one half of those women will have had at least one prior abortion. Nearly one third of all US women will undergo an abortion by age 45.

Keywords

Outpatient abortion Abortion Primary care gynecologist Counseling Safety 

References

  1. 1.
    Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health. 2006;38(2):90–6.CrossRefGoogle Scholar
  2. 2.
    Jones RK, Zolna MR, Henshaw SK, Finer LB. Abortion in the United States: incidence and access to services, 2005. Perspect Sex Reprod Health. 2008;40(1):6–16.CrossRefGoogle Scholar
  3. 3.
    Jones RK, Finer LB, Singh S. Characteristics of U.S. abortion patients, 2008. New York: Guttmacher Institute; 2010.Google Scholar
  4. 4.
    Guttmacher Institute. State facts about abortion. New York, http://www.quttmacher.org!pubslsfaalnewyork.html. 2006. Accessed 12 Apr 2010.Google Scholar
  5. 5.
    Eastwood KL, Kacmar JE, Steinauer J, Weitzen S, Boardman LA. Abortion training in the United States obstetrics and gynecology residency programs. Obstet Gynecol. 2006;108:303–8.CrossRefGoogle Scholar
  6. 6.
    O’Connell K, Jones H, Simon M, Saporta V, Paul M, Lichtenberg ES. First trimester surgical abortion practices: a survey of National Abortion Federation members. Contraception. 2009;79(5):385–92.CrossRefGoogle Scholar
  7. 7.
    Boonstra H, Gold R, Richards C, Finer L. Abortion in women’s lives. New York: Guttmacher Institute; 2006.Google Scholar
  8. 8.
    Charles VE, Polis CB, Sridhara SK, Blum RW. Abortion and long-tern mental health outcomes: a systematic review of the evidence. Contraception. 2008;78:436–50.CrossRefGoogle Scholar
  9. 9.
    American Psychological Association. Report of the APA Task Force on Mental Health and Abortion. (Online). Cited June 2010. URL http://www.apa.org/pi/women/programs/aborti on/index.aspx (n.d.)
  10. 10.
    Hogue C, Boardman L, Stotland N. Answering questions about long-term outcomes. In: Paul M, et al., editors. Management of unintended and abnormal pregnancy: comprehensive abortion care. Oxford: Wiley Blackwell; 2009. p. 259.Google Scholar
  11. 11.
    Breen AN, Mourn T, Bodtker AS, Ekeberg O. Predictors of anxiety and depression following pregnancy termination: a longitudinal five-year follow-up study. Acta Obstet Gynecol Xcand. 2006;85:317–23.CrossRefGoogle Scholar
  12. 12.
    Baker A, Beresford T. Informed consent, patient education, and counseling. In: Paul M, et al., editors. Management of unintended and abnormal pregnancy: comprehensive abortion care. Oxford: Wiley Blackwell; 2009. p. 57.Google Scholar
  13. 13.
    American College of Obstetrics and Gynecology. Medical management of abortion. ACOG Pract Bull. 2005;677:1–12.Google Scholar
  14. 14.
    Jain JK, Dutton C, Harwood B, Meckstroth KR, Mishell DR Jr. A prospective randomized, double blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective terminations of early pregnancy. Hum Reprod. 2002;17:1477–821.CrossRefGoogle Scholar
  15. 15.
    Carbonell JL, Rodriguez J, Velazco A, Tanda R, Sanchex C, Barambio S, Chami S, Valero F, Mari J, de Vargas F, Salvador I. Oral and vaginal misoprostol 800 micrograms every 8 h for early abortion. Contraception. 2003;67(6):457–62.CrossRefGoogle Scholar
  16. 16.
    Crenin MD, Shulman. Effect of non-steroidal anti-inflammatory drugs on the action of misoprostol in regimen for early abortion. Contraception. 1997;56:165–8.CrossRefGoogle Scholar
  17. 17.
    Clark W, Bracken H, Tanenhaus J, Schweikert S, Lichtenberg ES, Winikoff B. Alternatives to routine follow-up visit for early medical abortion. Obset Gynecol. 2010;115(2 pt 1):264–72.CrossRefGoogle Scholar
  18. 18.
    Perriera LK, Reeves MF, Chen BA, Hohmann HL, Hayes J, Crenin MD. Feasibility of telephone follow up after medication abortion. Contraception. 2010;81(2):143–9.CrossRefGoogle Scholar
  19. 19.
    Fjerstad M, Trussell J, Sivin I, Lichtenberg ES, Cullins V. Rates of serious infection after changes in regimens for medical abortion. N Engl J Med. 2009;361(2):145–51.CrossRefGoogle Scholar
  20. 20.
    Fischer M, et al. Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion. N Engl J Med. 2005;353:2352–60.CrossRefGoogle Scholar
  21. 21.
    Kapp N, Lohr PA, Ngo TD, Hayes JL. Cervical preparation for first trimester surgical abortion. Cochrane Database Syst Rev. 2010;17:2.Google Scholar
  22. 22.
    Renner RM, Jensen JT, Nichols MD, Edelman AB. Pain control in first-trimester surgical abortion: a systematic review of randomized controlled trials. Contraception. 2010;81(5):372–88.CrossRefGoogle Scholar
  23. 23.
    O’Connell K, Jones HE, Simon M, Saporta V, Paul M, Lichtenberg ES, National Abortion Federation Members. First-trimester surgical abortion practices: a survey of National Abortion Federation members. Contraception. 2009;79(5):385–92.CrossRefGoogle Scholar
  24. 24.
    Strauss L, Gamble S, Parker W, et al. Abortion surveillance-United States. MMWR Morb Mortal Wkly Rep. 2007;56(55–91):1–33.Google Scholar
  25. 25.
    Hammond C. Recent advances in second-trimester abortion: an evidence-based review. Am J Obstet Gynecol. 2009;200:347–56.CrossRefGoogle Scholar
  26. 26.
    Su LL, Biswas A, Choolani M, Kalaichelvan V, Singh K. A prospective, randomized comparison of vaginal misoprostol versus intra-amniotic prostaglandins for midtrimester termination of pregnancy. Am J Obstet Gynecol. 2005;193:1410–4.CrossRefGoogle Scholar
  27. 27.
    Owen J, Hauth JC. Vaginal misoprostol vs concentrated oxytocin plus low-dose prostaglandin E2 for second trimester pregnancy termination. J Matern Fetal Med. 1999;8:48–50.PubMedGoogle Scholar
  28. 28.
    Andersen LF, Poulsen HK, Sorensen SS, Christensen BM, Sponland G, Skjeldestad FE. Termination of 2nd trimester pregnancy with gemeprost vaginal pessaries and intra-amniotic Pgf2-alpha: a comparative study. Eur J Obstet Gynecol Reprod Biol. 1989;31:1–7.CrossRefGoogle Scholar
  29. 29.
    Cameron IT, Baird DT. The use of 16, 16-dimethyl-trans-delta-2 prostaglandin-El methyl-ester (gemeprost) vaginal pessaries for the termination of pregnancy in the early 2nd trimester: a comparison with extra-amniotic prostaglandin-E2. Br J Obstet Gynaecol. 1984;91:1136–40.CrossRefGoogle Scholar
  30. 30.
    Blanchard K, Clark S, Winikoff B, Gaines G, Kabani G, Shannon C. Misoprostol for women’s health: a review. Obstet Gynecol. 2002;99:316–32.PubMedGoogle Scholar
  31. 31.
    Ramin KD, Ogburn PL, Daninlenko DR, Ramsey PS. High-dose oral misoprostol for mid-trimester pregnancy interruption. Gynecol Obstet Investig. 2002;54:176–9.CrossRefGoogle Scholar
  32. 32.
    Bebbington MW, Kent N, Lim K, et al. A randomized controlled trial comparing two protocols for the use of misoprostol in midtrimester pregnancy termination. Am J Obstet Gynecol. 2002;187:853–7.CrossRefGoogle Scholar
  33. 33.
    Wong KS, Ngai CSW, Yeo ELK, Tang LCH, Ho PC. A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: a randomized comparative trial. Hum Reprod. 2000;15:709–12.CrossRefGoogle Scholar
  34. 34.
    Jain JK, Mishell DR. A comparison of intravaginal misoprostol with prostaglandin E2 for termination of second-trimester pregnancy. N Engl J Med. 1994;331:290–3.CrossRefGoogle Scholar
  35. 35.
    Herabutya Y, Prasertsawat PO. Second trimester abortion using intravaginal misoprostol. nt J Gynaecol Obstet. 1998;60:161–5.Google Scholar
  36. 36.
    Dickinson JE, Evans SF. The optimization of intravaginal misoprostol dosing schedules in second trimester pregnancy termination. Am J Obstet Gynecol. 2002;186:470–4.CrossRefGoogle Scholar
  37. 37.
    Hammond C. Recent advances in second trimester abortion. Am J Obstet Gynecol. 2009;200(4):347–56.CrossRefGoogle Scholar
  38. 38.
    Ashok PW, Templeton A, Wagaarachchi PT, Flett GMM. Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. Contraception. 2004;69:51–8.CrossRefGoogle Scholar
  39. 39.
    Pongsatha S, Tongsong T. Intravaginal misoprostol for pregnancy termination. Int J Gynaecol Obstet. 2004;87:176–7.CrossRefGoogle Scholar
  40. 40.
    Bygdeman M, Swahn ML. Progesterone receptor blockage: effect on uterine contractility and early pregnancy. Contraception. 1985;32:45–51.CrossRefGoogle Scholar
  41. 41.
    World Health Organization. Safe abortion: technical and policy guidance for health systems. Geneva: World Health Organization; 2003.Google Scholar
  42. 42.
    Royal College of Obstetricians and Gynecologists. The care of women requesting induced abortion. London: Royal College of Obstetricians and Gynecologists; 2004.Google Scholar
  43. 43.
    Tang OS, Chan CCW, Kan ASY, Ho PC. A prospective randomized comparison of sublingual and oral misoprostol when combined with mifepristone for medical abortion at 12–20 weeks gestation. Hum Reprod. 2005;20:3062–6.CrossRefGoogle Scholar
  44. 44.
    Rose SB, Shand C, Simmons A. Mifepristone-and misoprostol-induced mid-trimester termination of pregnancy: a review of 272 cases. Aust N Z J Obstet Gynaecol. 2006;46:479–85.CrossRefGoogle Scholar
  45. 45.
    Hamoda H, Ashok PW, Flett GM, Templeton A. Analgesia requirements and predictors of analgesia use for women undergoing medical abortion up to 22 weeks of gestation. BJOG. 2004;111:996–1000.CrossRefGoogle Scholar
  46. 46.
    Kafrissen ME, Barke MW, Workman P, et al. Coagulopathy and induced abortion methods: rates and relative risks. Am J Obstet Gynecol. 1983;147:344–5.CrossRefGoogle Scholar
  47. 47.
    Kapp N, Todd CS, Yadgarova KT, et al. A randomized comparison of misoprostol to intrauterine instillation of hypertonic saline plus a prostaglandin F2 analogue for second trimester induction termination in Uzbekistan. Contraception. 2007;76:461–6.CrossRefGoogle Scholar
  48. 48.
    Green J, Borgatta L, Sia M, et al. Intervention rates for placental removal following induction abortion with misoprostol. Contraception. 2007;76:310–3.CrossRefGoogle Scholar
  49. 49.
    Marinoni E, Santoro M, Vitagliano MP, Patella A, Cosmi EV, Ci Lorio R. Intravaginal gemeprost and second-trimester pregnancy termination in the scarred uterus. Int J Gynaecol Obstet. 2007;97:35–9.CrossRefGoogle Scholar
  50. 50.
    Daponte A, Nzewenga G, Dimopoulos KD, Guidozzi F. The use of vaginal misoprostol for second trimester pregnancy termination in women with previous single cesarean section. Contraception. 2006;74:324–7.CrossRefGoogle Scholar
  51. 51.
    Shammas AG, Momani MD. Misoprostol for termination of second trimester pregnancy in a scarred uterus. Saudi Med J. 2006;27:1173–6.PubMedGoogle Scholar
  52. 52.
    Mazouni C, Provensal M, Porcu G, et al. Termination of pregnancy in patients with prior cesarean section. Contraception. 2006;73:244–8.CrossRefGoogle Scholar
  53. 53.
    Daskalakis GJ, Mesogitis SA, Papantoniou NE, Moulopoulos GG, Papapanagiotou AA, Antsaklis AJ. Misoprostol for second trimester pregnancy termination in women with prior cesarean section. BJOG. 2005;112:97–9.CrossRefGoogle Scholar
  54. 54.
    Freeman EW. Abortion: subjective attitudes and feelings. Fam Plan Perspect. 1978;10:150–5.CrossRefGoogle Scholar
  55. 55.
    Rooks JB, Cates W. Emotional impact of D and E vs instillation. Fam Plan Perspect. 1977;9:276–7.CrossRefGoogle Scholar
  56. 56.
    Kaltreider NB, Goldsmith S, Margolis AJ. The impact of midtrimester abortion techniques on patients and staff. Am J Obstet Gynecol. 1979;135:235–8.CrossRefGoogle Scholar
  57. 57.
    Cowett A, Golub R, Grobman W. Cost-effectiveness of dilation and evacuation versus the induction of labor for second-trimester pregnancy termination. Am J Obstet Gynecol. 2006;194:768–73.CrossRefGoogle Scholar
  58. 58.
    Grimes DA, Smith MS, Witham AD. Mifepristone and misoprostol versus dilation and evacuation for midtrimester abortion: a pilot randomized controlled trial. BJOG. 2004;111:148–53.CrossRefGoogle Scholar
  59. 59.
    Darney PD, Sweet RL. Routine intraoperative ultrasonography for second trimester abortion reduces incidence of uterine perforation. J Ultrasound Med. 1989;8:71–5.CrossRefGoogle Scholar
  60. 60.
    Schulz KF, Grimes DA, Christensen DD. Vasopressin reduces blood loss from second-trimester dilatation and evacuation abortion. Lancet. 1985;2:353–6.CrossRefGoogle Scholar
  61. 61.
    Maclsaac L, Grossman D, Balistreri E, Darney P. A randomized controlled trial of laminaria, oral misoprostol, and vaginal misoprostol before abortion. Obstet Gynecol. 1999;93:766–70.Google Scholar
  62. 62.
    Ngai SW, Chan YM, Tang OS, Ho PC. The use of misoprostol for pre-operative cervical dilatation prior to vacuum aspiration: a randomized trial. Hum Reprod. 1999;14:2139–42.CrossRefGoogle Scholar
  63. 63.
    El-Refaey H, Calder L, Wheatley DN, Templeton A. Cervical priming with prostaglandin El analogues, misoprostol and gemeprost. Lancet. 1994;343:1207–9.CrossRefGoogle Scholar
  64. 64.
    Todd CS, Soler M, castleman L, Rogers MK, Blumenthal PD. Buccal misoprostol for second trimester pregnancy termination. Contraception. 2002;65:415–8.CrossRefGoogle Scholar
  65. 65.
    Patel A, Talmont E, Morfesis J, et al. Adequacy and safety of buccal misoprostol for cervical preparation prior to termination of second trimester pregnancy. Contraception. 2006;73:420–30.CrossRefGoogle Scholar
  66. 66.
    Goldberg A, Drey E, Whitaker A, Kang M, Meckstroth K, Darney P. Misoprostol compared with laminaria before early second trimester surgical abortion: a randomized trial. Obstet Gynecol. 2005;106:234–41.CrossRefGoogle Scholar
  67. 67.
    Edelman A, Buckmaster J, Goetsch M, Nichols M, Jensen J. Cervical preparation using laminaria with adjunctive buccal misoprostol before second-trimester dilation and evacuation procedures: a randomized clinical trial. Am J Obstet Gynecol. 2006;194:425–30.CrossRefGoogle Scholar
  68. 68.
    Darney PD, Dorward K. Cervical dilation before first-trimester elective abortion: a controlled comparison of meteneprost, laminaria and hypan. Obstet Gynecol. 1987;70:397–400.PubMedGoogle Scholar
  69. 69.
    Chen JK, Elder MG. Preoperative cervical dilatation by vaginal pessaries containing prostaglandin El analogue. Obstet Gynecol. 1983;62:339–42.CrossRefGoogle Scholar
  70. 70.
    Lauersen HN, Den T, Iliescu C, et al. Cervical priming prior to dilatation and evacuation: a comparison of methods. Am J Obstet Gynecol. 1982;14:890–4.CrossRefGoogle Scholar
  71. 71.
    Carbonell J, Gallego F, Llorente M, et al. Vaginal vs sublingual misoprostol with mifepristone for cervical priming in second-trimester abortion by dilation and evacuation: a randomized clinical trial. Contraception. 2007;75:230–7.CrossRefGoogle Scholar
  72. 72.
    Hammond C, Chasen S. Dilation and evacuation. In: Paul M, Lichtenberg S, Borgatta L, et al., editors. Management of unintended and abnormal pregnancy: comprehensive abortion care. Oxford: Wiley Blackwell; 2003. p. 167.Google Scholar
  73. 73.
    Jackson RA, Teplin VL, Drey EA, et al. Digoxin to facilitate late second-trimester abortion: a randomized, masked, placebo-controlled trial. Obstet Gynecol. 2001;97:471–6.PubMedGoogle Scholar
  74. 74.
    Molaei M, Jones HE, Weiselberg T, et al. Effectiveness and safety of digoxin to induce fetal demise prior to second-trimester abortion. Contraception. 2008;77:223–5.CrossRefGoogle Scholar
  75. 75.
    Lawson HW, Frye A, Atrash HK, et al. Abortion mortality, United States, 1972–1987. Am J Obstet Gynecol. 1994;171:1365–72.CrossRefGoogle Scholar
  76. 76.
    Hoyert DL. Maternal mortality and related concepts: National Center for Health Statistics. Vital Health Stat. 2007;3:33.Google Scholar
  77. 77.
    Kalish RB, Chasen ST, Rosenzweig LB, Rashbaum WK, Chervenak FA. Impact of midtrimester dilation and evacuation on subsequent pregnancy outcome. Am J Obstet Gynecol. 2002;187:882–5.CrossRefGoogle Scholar
  78. 78.
    Jackson JE, Grobman WA, Haney E, Casele H. Mid-trimester dilation and evacuation with laminaria does not increase the risk for severe subsequent pregnancy complications. Int J Gynaecol Obstet. 2007;96:12–5.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Obstetrics and Gynecology, Northwestern Memorial HospitalNorthwestern University Feinberg School of MedicineChicagoUSA

Personalised recommendations